Brian Armstrong's NewLimit raises $435M to push…

NewLimit, the longevity biotech co-founded by Coinbase CEO Brian Armstrong, has closed a $435 million Series C round led by Founders Fund. New investors Thrive Capital, Greenoaks, and Quiet Capital joined the round, while existing backers Kleiner Perkins and Eli Lilly Ventures also participated. The company plans to advance its first age-reprogramming drug into human trials next year.

Why it matters

A $435 million Series C for a longevity biotech is a significant capital event — this is not seed-stage moonshot money, it is late-stage institutional conviction. Founders Fund leading the round, alongside pharma-adjacent Eli Lilly Ventures, signals that the age-reprogramming thesis is attracting both venture and established life-sciences capital simultaneously. Armstrong's profile as Coinbase's CEO brings a layer of cross-sector visibility that few biotech founders command, drawing attention from investors who might otherwise overlook early longevity science.

Market impact

The move into human trials next year is the concrete milestone to watch. If NewLimit's first age-reprogramming candidate clears early safety hurdles, it validates a category that has attracted billions in aggregate over the past three years — from Altos Labs to Calico. For crypto-adjacent investors tracking Armstrong, this round also reinforces the pattern of crypto-native founders deploying capital and credibility into deep-tech longevity bets, a trend that could attract further crossover attention to the sector.